Overview
This book is a compendium of the worldwide ocular stem cell, gene therapy, optogenetic, and other miscellaneous studies treating Retinitis Pigmentosa registered with Clinicaltrials.gov. Clinicaltrials.gov is the largest website listing of registered clinical research studies in the world. The study title and the Clinical Trial Number is provided in order to make it easier for the reader to obtain further information. The book contains chapters that act as an introduction to Retinitis Pigmentosa, as well as discussion and analysis of the studies. References are also included for the readers’ use. Clinical Trials in Retinitis Pigmentosa Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
Full Product Details
Author: Jeffrey N. Weiss
Publisher: Springer International Publishing AG
Imprint: Springer International Publishing AG
Edition: 2024 ed.
ISBN: 9783031587986
ISBN 10: 3031587987
Pages: 286
Publication Date: 21 August 2024
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: Manufactured on demand
We will order this item for you from a manufactured on demand supplier.
Author Information
Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology. Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss’ inventions worldwide. Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions. Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.
